The risk of recurrent venous thromboembolism

Vasa - Journal of Vascular Diseases

Volumn 31, Issue 3, 2002, Pages 163-166

  Kyrle, Paul A ^a   Eichinger, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticoagulation; Clotting defects; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; CANCER; CHEMOPROPHYLAXIS; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; THROMBOEMBOLISM; TREATMENT INDICATION; ARTICLE; EVALUATION; LONG TERM CARE; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; LONG-TERM CARE; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0036674007     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.31.3.163     Document Type: Review

References (27)

1. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis
2. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT Study
3. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
4. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene
5. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden
6. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism
7. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism
8. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
9. The management of thrombosis in the antiphospholipid-antibody syndrome
10. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis
11. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism
12. Hemorrhagic complications of anticoagulant treatment
13. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of anticoagulation
14. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism
15. High levels of coagulation factor XI as a risk factor for venous thrombosis
16. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy
17. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis
18. The long-term clinical course of acute deep venous thrombosis
19. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism
20. Risk factors for venous thrombotic disease
21. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism
22. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
23. Anticardiolipin anti-bodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anti-coagulant therapy
24. The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolism
25. Risk of subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis
26. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants
27. High levels of factor IX increase the risk of venous thrombosis